SLC5A2 and chronic kidney disease: While it is generally recommended that kidney function does not need to be monitored after initiation of an SGLT2 inhibitor in most patients with CKD, in individuals deemed at risk of AKI, review of hydration status and testing of kidney function 4 weeks after initiation has been suggested, although, in most cases, findings will not result in alteration of SGLT2 inhibition or dosing.